TrialsgrambetaRCTs are beautiful

2019 ESC/EAS Guidelines for the management of dyslipidaemias (with 2025 Focused Update)

This guideline cites 9 of the 199 landmark trials in our Cardiology register.

Issued by
ESC/EAS
Year
2019
Source
Mach F, Baigent C, et al. Eur Heart J. 2020;41(1):111–188. Focused Update: Eur Heart J. 2025;46(42):4359–4378.doi 10.1093/eurheartj/ehz455

The 2019 ESC/EAS guideline set the "lower is better" LDL-cholesterol targets and risk-based intensity of lipid lowering; the 2025 Focused Update reinforced early combination therapy and the role of newer agents. The register's landmark statin, non-statin and residual-risk trials are grouped by mechanism below.

Statins: intensity & outcomes3

  • 2008JUPITER⁠Cardiology · Lipids · StatinsIn 17,802 adults with LDL < 130 mg/dL and hsCRP ≥ 2 mg/L, rosuvastatin reduced major vascular events versus placebo.HR 0.56Read →
  • 2004PROVE-IT⁠Cardiology · Lipids · StatinsIn 4,162 patients after acute coronary syndrome, intensive atorvastatin 80 mg reduced death or major cardiovascular events compared with moderate pravastatin 40 mg (16% relative reduction, P=0.005).22.4% vs 26.3%Read →
  • 19944S Core⁠Cardiology · Lipids · StatinsIn 4,444 patients with CAD and total cholesterol 5.5–8.0 mmol/L, simvastatin reduced all-cause mortality compared with placebo.RR 0.7Read →

Non-statin LDL lowering (ezetimibe, PCSK9, bempedoic acid)4

  • 2023CLEAR Outcomes⁠Cardiology · Lipids · Non-statin LDLIn 13,970 statin-intolerant patients, bempedoic acid reduced major adverse cardiovascular events compared with placebo.HR 0.87Read →
  • 2018ODYSSEY OUTCOMES⁠Cardiology · Lipids · PCSK9 inhibitorIn 18,924 patients with recent acute coronary syndrome on high-intensity statin, alirocumab reduced major adverse cardiovascular events compared with placebo (HR 0.85, 95% CI 0.78-0.93).HR 0.8595% CI 0.78-0.93Read →
  • 2017FOURIER⁠Cardiology · Lipids · PCSK9iIn 27,564 patients with ASCVD on statins, evolocumab reduced CV death, MI, stroke, hosp UA or revasc compared with placebo.HR 0.8595% CI 0.79-0.92Read →
  • 2015IMPROVE-IT⁠Cardiology · Lipids · Non-statin LDLIn 18,144 patients post-ACS, ezetimibe added to simvastatin further reduced CV death, MI, UA, revasc or stroke compared with simvastatin alone.HR 0.94Read →

Residual risk: triglycerides & inflammation2

  • 2019REDUCE-IT⁠Cardiology · Lipids · TriglyceridesIn 8,179 statin-treated patients with high triglycerides, icosapent ethyl reduced major adverse cardiovascular events compared with placebo.HR 0.75Read →
  • 2017CANTOS⁠Cardiology · Lipids · Anti-inflammatoryIn 10,061 patients with prior MI and elevated CRP, canakinumab reduced recurrent cardiovascular events compared with placebo.HR 0.8595% CI 0.74-0.98Read →

Cited landmark trials not yet in the register3

Further landmark trials this guideline cites that are not (yet) covered in our register. Each links out to the study for further reading.

  • 2002HPS (Heart Protection Study)

    Simvastatin cut vascular events across a broad high-risk population.

  • 2020ORION-10/-11

    Inclisiran (siRNA) for sustained LDL-cholesterol lowering.

  • 2022PROMINENT

    Pemafibrate did not reduce CV events despite lowering triglycerides.

Every trial shown is one this guideline actually cites: each link was checked against the guideline's own reference list, and the few that a machine cannot match, a trial cited through a later follow-up, or a NICE guideline, which carries no DOI, were verified by hand against the full text. This is not the guideline's complete reference list, only the landmark trials it cites that our register holds.